Takeda Pharmaceutical, Astellas Pharma, and Sumitomo Mitsui Banking (SMBC) have announced the signing of a master agreement to establish a joint venture (JV) focused on the incubation of early drug discovery programmes.
The partnership aims to foster innovative therapeutics, covering the entire drug discovery process from research to the launch of startups, primarily originating from Japan.
Go deeper with GlobalData
Takeda and Astellas will support the JV by sharing their global research and development expertise to promote open innovation in early-stage drug discovery.
With an initial capital of approximately Y600m ($3.87m), the new JV company will be located at Shonan Health Innovation Park in Japan.
Takeda will have a 33.4% stake in the new company while Astellas and SMBC will have 33.4% and 33.2% stakes, respectively.
The new company will concentrate on three primary objectives: advancing Japanese-originating drug discovery programmes to the global market; nurturing drug discovery technology and entrepreneurship; and enhancing Japan’s drug discovery ecosystem through high-quality startups.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFurthermore, the JV plans to initiate incubation activities by collaborating with academic institutions, pharmaceutical companies, and startups throughout Japan.
This collaboration aims to provide access to early drug discovery programmes with the potential to transform the industry.
The three companies will further discuss the details of the agreement for the completion of the JV inception and begin its operations.
Last month, the US Food and Drug Administration approved Takeda’s Entyvio subcutaneous administration as a maintenance therapy to treat adults with moderately to severely active Crohn’s disease.
